scholarly journals A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients

2021 ◽  
Vol 43 (1) ◽  
Author(s):  
Yuto Matsushita ◽  
Yuji Iwashita ◽  
Shunsuke Ohtsuka ◽  
Ippei Ohnishi ◽  
Takashi Yamashita ◽  
...  

Abstract Background DNA adducts, covalent modifications to DNA due to exposure to specific carcinogens, cause the mispairing of DNA bases, which ultimately results in DNA mutations. DNA methylation in the promoter region, another type of DNA base modification, alters the DNA transcription process, and has been implicated in carcinogenesis in humans due to the down-regulation of tumor suppressor genes. Difficulties are associated with demonstrating the existence of DNA adducts or chemically modified bases in the human urological system. Apart from aristolochic acid-DNA adducts, which cause urothelial carcinoma and endemic nephropathy in a particular geographical area (Balkan), limited information is currently available on DNA adduct profiles in renal cell carcinoma and upper urinary tract urothelial carcinoma, including renal pelvic cancer and ureteral cancer. Method To elucidate the significance of DNA adducts in carcinogenesis in the urothelial system, we investigated 53 DNA adducts in the non-tumoral renal parenchyma and non-tumoral renal pelvis of patients with renal cell carcinoma, upper urinary tract urothelial carcinoma, and other diseases using liquid chromatography coupled with tandem mass spectrometry. A comparative analysis of tissue types, the status of malignancy, and clinical characteristics, including lifestyle factors, was performed. Results C5-Methyl-2′-deoxycytidine, C5-hydroxymethyl-2′-deoxycytidine (5hmdC), C5-formyl-2′-deoxycytidine, 2′-deoxyinosine, C8-oxo-2′-deoxyadenosine, and C8-oxo-2′-deoxyguanosine (8-OHdG) were detected in the renal parenchyma and renal pelvis. 8-OHdG was more frequently detected in the renal pelvis than in the renal cortex and medulla (p = 0.048 and p = 0.038, respectively). 5hmdC levels were significantly lower in the renal pelvis of urothelial carcinoma patients (n = 10) than in the urothelium of patients without urothelial carcinoma (n = 15) (p = 0.010). Regarding 5hmdC levels in the renal cortex and medulla, Spearman’s rank correlation test revealed a negative correlation between age and 5hmdC levels (r = − 0.46, p = 0.018 and r = − 0.45, p = 0.042, respectively). Conclusions The present results revealed a reduction of 5hmdC levels in the non-tumoral urinary tract mucosa of patients with upper urinary tract urothelial carcinoma. Therefore, the urothelial cell epithelia of patients with upper urinary tract cancer, even in non-cancerous areas, may be predisposed to urothelial cancer.

2012 ◽  
Vol 136 (8) ◽  
pp. 907-910 ◽  
Author(s):  
Allison Young ◽  
Lakshmi P. Kunju

We report the case of a high-grade carcinoma involving the kidney in a young male with renal vein thrombosis and review the differential diagnosis and immunohistochemical workup. High-grade neoplasms involving the renal sinus include collecting duct carcinomas (CDCs), renal medullary carcinomas (RMCs), invasive high-grade urothelial carcinoma (UC) of the upper urinary tract, clear cell renal cell carcinoma, and type 2 papillary renal cell carcinoma. Distinguishing UC from CDC and RMC is problematic in small biopsy samples. The diagnosis of CDC (a rare, aggressive subtype of renal cell carcinoma) is challenging and requires the exclusion of UC. Renal medullary carcinoma is characterized by an appropriate clinical setting and consistent loss of nuclear expression of integrase interactor 1 (INI-1). A panel consisting of p63, paired box gene 8 (PAX8), and INI-1 is most optimal in distinguishing UC from CDC and RMC. A subset of urothelial carcinoma of upper urinary tract may be positive with PAX8.


2013 ◽  
Vol 3 (1) ◽  
pp. 64 ◽  
Author(s):  
Mike Leveridge ◽  
Phillip A. Isotalo ◽  
Alexander H. Boag ◽  
Jun Kawakami

Renal cell carcinoma (RCC) and urothelial carcinoma of the upperurinary tract are not uncommon urological malignancies. Theirsimultaneous occurrence in a patient is, however, extraordinarilyrare. We report the case of a patient who underwent laparoscopicnephrectomy for suspected RCC. Preoperative imaging wassuspicious for renal pelvic involvement, which was confirmedupon bivalving the fresh specimen at the time of surgery, with thediscovery of a separate urothelium-based lesion. We discuss thisrare occurrence and our management approach.Individuellement, l’hypernéphrome et le carcinome urothélial desvoies urinaires supérieures ne sont pas des tumeurs urologiquesrares. Leur survenue simultanée chez un même patient est cependantextrêmement rare. La reconnaissance préopératoire ou intraopératoireest cruciale afin que soit effectuée la résection urétéralerequise. Nous décrivons un cas d’hypernéphrome et de carcinomeurothélial simultanés et homolatéraux.


2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Shigenori Kakutani ◽  
Haruki Kume ◽  
Yoshikazu Hirano ◽  
Toshihiko Wakita ◽  
Yukio Homma

We describe an unusual case of renal cell carcinoma (RCC) involving the entire upper urinary tract. A 51-year-old female was referred to us because of macroscopic hematuria. Computed tomography revealed a renal tumor filling renal pelvis and ureter, which turned to be a clear cell RCC after nephroureterectomy.


2017 ◽  
Vol 6 (2) ◽  
pp. 110
Author(s):  
JayalakshmyPayippat Leelamma ◽  
Lillykutty Pothen ◽  
NairParvati Ramachandran

2003 ◽  
Vol 51 (8) ◽  
pp. 1097-1099 ◽  
Author(s):  
Cord Langner ◽  
Manfred Ratschek ◽  
Oleksiy Tsybrovskyy ◽  
Luigi Schips ◽  
Richard Zigeuner

P63 is essential for the differentiation of normal urothelium and is also expressed in transitional cell carcinoma (TCC) of the bladder. We investigated p63 immunoreactivity in upper urinary tract TCC ( n = 53) and in renal-cell carcinoma (RCC; n = 188) using a tissue microarray technique. P63 expression was detected in 51/53 (96.2%) TCCs, showing decreased expression in high-stage (pT1 and pT2 100%; pT3 90.9%) and poorly differentiated (G1 and G2 100%; G3 92%) tumors. All RCCs were negative for p63. P63 proved to be a helpful tool, even in poorly differentiated and undifferentiated renal malignancies, to distinguish TCC from RCC.


Sign in / Sign up

Export Citation Format

Share Document